Cryoglobulinemia medical therapy
|
Cryoglobulinemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cryoglobulinemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Cryoglobulinemia medical therapy |
|
Risk calculators and risk factors for Cryoglobulinemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Feham Tariq, MD [2]
Overview
Medical Therapy
The medical treatment of cryoglobulinemia depends on the underlying etiology, nature and progression of the disease. The main indication for therapy is to halt the progressive end organ damage affecting the kidneys, skin, gastrointestinal system, central nervous system and the extremities.
Medical Therapy
The main pharmacotherapy for each type of cryoglobulinemia is discussed below:
Assymptomatic cryoglobulinemia
This type of cryoglobulinemia requires no medical treatment.
Secondary cryoglobulinemia
This category includes type 1 and mixed cyroglobulinemia. The goal of treatment for secondary type is as follows:
- Conservative management
- Immunosuppressive agents
- Plasmapheresis
Immunosuppressive agents
The main aim of immunosuppressive therapy in cryoglobulinemia is its employment for the patients having rapidly progressive, organ-threatening or like-threatening course of the disease regardless of the underlying cause.
- Indications for immunosuppressive therapy:
The indications for using immunosuppressive therapy are as follows:
- Digital ischemia leading to amputation
- Gastrointestinal vasculitis resulting in abdominal pain
- Heart failure
- Pulmonary vasculitis associated with alveolar hemorrhage
- Central nervous system vasculitis that presents as stroke
- Glomerulonephritis associated with nephrotic range proteinuria
Choice of immunosuppressive therapy:
The patients selected for immunosuppressive therapy are preferably initiated with rituximab along with pulsed doses of glucocorticoids.
Ritximab Regimen:
- Preferred regimen (1): Four infusions of rituximab 375 mg/m2 at weekly intervals (day 0, day 7, day 14, day 21).
- Preferred regimen (2): Two infusions of ritximab 1000 mg IV seperated by two weeks interval (day 0 and day 14).
- Preferred regimen (3): Four infusions of rituximab 375 mg/m2 at weekly intervals (day 0, day 7, day 14, day 21) followed by additional doses at day 49 and day 77.